Trial Outcomes & Findings for Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED) (NCT NCT00705263)

NCT ID: NCT00705263

Last Updated: 2009-08-25

Results Overview

Participants were asked to evaluate the training they received in the proper use of the pen, the preparation and injection of the medicine, and to provide their subjective impressions about the use of the PegIntron pen. Satisfaction was defined as score 5 or above on a 7-point grading scale.

Recruitment status

COMPLETED

Target enrollment

113 participants

Primary outcome timeframe

After 4 weeks of treatment.

Results posted on

2009-08-25

Participant Flow

113 patients were enrolled in the study; however, data were available for 110 subjects

Participant milestones

Participant milestones
Measure
Patients With Chronic Hepatitis C
Patients with chronic hepatitis C who are treated with the PegIntron pen plus Rebetol will answer questions on the patient questionnaire.
Overall Study
STARTED
110
Overall Study
COMPLETED
108
Overall Study
NOT COMPLETED
2

Reasons for withdrawal

Reasons for withdrawal
Measure
Patients With Chronic Hepatitis C
Patients with chronic hepatitis C who are treated with the PegIntron pen plus Rebetol will answer questions on the patient questionnaire.
Overall Study
Withdrawal by Subject
2

Baseline Characteristics

Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Patients With Chronic Hepatitis C
n=110 Participants
Patients with chronic hepatitis C who are treated with the PegIntron pen plus Rebetol will answer questions on the patient questionnaire.
Age Continuous
40.25 years
STANDARD_DEVIATION 12.71 • n=93 Participants
Sex/Gender, Customized
Female
37 participants
n=93 Participants
Sex/Gender, Customized
Male
68 participants
n=93 Participants
Sex/Gender, Customized
Not provided
5 participants
n=93 Participants
Region of Enrollment
Slovenia
110 participants
n=93 Participants

PRIMARY outcome

Timeframe: After 4 weeks of treatment.

Population: Patients with chronic hepatitis C treated with PegIntron pen plus Rebetol

Participants were asked to evaluate the training they received in the proper use of the pen, the preparation and injection of the medicine, and to provide their subjective impressions about the use of the PegIntron pen. Satisfaction was defined as score 5 or above on a 7-point grading scale.

Outcome measures

Outcome measures
Measure
Patients Treated With PegIntron Pen Plus Rebetol
n=110 Participants
Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.
Helpfulness of the brochure: instructions
96 Satisfied Participants
Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.
Injection technique: correctly injected
104 Satisfied Participants
Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.
No difficulties injecting
102 Satisfied Participants
Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.
Overall impression
102 Satisfied Participants
Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.
Satisfaction with the pen
102 Satisfied Participants
Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.
Ease of setting the dose
101 Satisfied Participants
Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.
Ease of use of the pen
101 Satisfied Participants
Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.
Convenience of use of the pen
101 Satisfied Participants
Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.
Easy injection
98 Satisfied Participants
Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.
Correct dose
98 Satisfied Participants
Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.
Overall helpfullness of the brochure
94 Satisfied Participants
Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.
Helpfulness of the brochure: advice
91 Satisfied Participants
Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.
Helpfulness of the brochure: general information
90 Satisfied Participants
Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.
Difficulty of preparing the pen
90 Satisfied Participants
Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.
Time required to prepare the pen
88 Satisfied Participants

Adverse Events

Patients With Chronic Hepatitis C

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Head, Clinical Trials Registry & Results Disclosure Group

Schering-Plough

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: LTE60